Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
Sumire.Kitahara (talk | contribs)
editor
165 edits
No edit summary
Formated Author Names
Line 289: Line 289:
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Disease
|(Rabail Aslam, MD)
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
Shashi Shetty, Ph.D.
|7/1/24
|7/1/24
Line 306: Line 306:
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|
|
Line 322: Line 323:
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|
|
Line 386: Line 388:
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|Xinxiu Xu (trainee);
Malini Sathanoori, Ph.D.
|4/15/25
|4/15/25
|
|
Line 402: Line 405:
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|(Rabail Aslam, MD)
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
Shashi Shetty, Ph.D.
|7/1/24
|7/1/24
Line 435: Line 438:
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Disease
|Eric McGinnis, MD, Fatma Al-Bulushi (trannee)
|Eric McGinnis, MD;
Fatma Al-Bulushi (trannee)
|12/20/23
|12/20/23
|
|
Line 470: Line 474:
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|Xinxiu Xu (trainee);
Malini Sathanoori, Ph.D.
|4/15/25
|4/15/25
|
|
Line 699: Line 704:
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|(Rabail Aslam, MD)
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
Shashi Shetty, Ph.D.
|7/1/24
|7/1/24
Line 848: Line 853:
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|
|
Line 944: Line 950:
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Disease
|(Rabail Aslam, MD)
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
Shashi Shetty, Ph.D.
|7/1/24
|7/1/24
Line 1,009: Line 1,015:
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Disease
|(Rabail Aslam, MD)
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
Shashi Shetty, Ph.D.
|7/1/24
|7/1/24
Line 1,169: Line 1,175:
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|12/22/24 Emailed 9/4/2025 to remind
Line 1,185: Line 1,192:
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|12/22/24 Emailed 9/4/2025 to remind
Line 1,201: Line 1,209:
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|12/22/24 Emailed 9/4/2025 to remind
Line 1,520: Line 1,529:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Disease
|Lei Zhang and Michelle Fan (trainee)
|Lei Zhang;
Michelle Fan (trainee)
|8/8/2024
|8/8/2024
|
|
Line 1,584: Line 1,594:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang and Michelle Fan (trainee)
|Lei Zhang;
Michelle Fan (trainee)
|8/8/2024
|8/8/2024
|
|
Line 1,658: Line 1,669:
|Assigned 12/19/2022 with completion date of 1/19/2023
|Assigned 12/19/2022 with completion date of 1/19/2023
|-
|-
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa,


Renee Eigsti, MD, Pathology Services of Kalamazoo
Renee Eigsti, MD, Pathology Services of Kalamazoo,


Honey Reddi, PhD, Belay Diagnostics
Honey Reddi, PhD, Belay Diagnostics
Line 1,670: Line 1,681:
|
|
|-
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee);
Shivani Golem
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Hairy Cell Leukemia
Line 2,022: Line 2,034:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee);
Andrew Siref as mentor
|3/22/24|| ||Pending|| ||GC|| ||
|3/22/24|| ||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,348: Line 2,361:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
Zhenya Tang
|4/14/25||7/14/25
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
9/4/2025 Sent E-mail reminder to Dr. Tang
Line 2,425: Line 2,439:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee);
Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| || || ||SK|| ||
Line 2,466: Line 2,481:
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Parastou Tizro, MD (trainee); Celeste Eno, PhD
|Parastou Tizro, MD (trainee);
Celeste Eno, PhD
|3/17/2024
|3/17/2024
|
|
Line 2,496: Line 2,512:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); Michelle Don, MD, MS
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
|3/17/2024 (trainee name added on 9/9/24 by JH)
|3/17/2024 (trainee name added on 9/9/24 by JH)
|6/30/24
|6/30/24
Line 2,539: Line 2,556:
|
|
|-
|-
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||8/31/2024
|Pending
|Pending
Line 2,549: Line 2,567:
|
|
|-
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
|3/19/2024
|3/19/2024
| ||Pending
| ||Pending
Line 2,559: Line 2,577:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee);


Andrew Siref, MD
Andrew Siref, MD
Line 2,580: Line 2,598:
|
|
|-
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024
|7/1/2024
|8/31/224
|8/31/224
Line 2,591: Line 2,610:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||8/31/2024
|Pending
|Pending
Line 2,627: Line 2,647:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
Sumire Kitahara, MD
|6/30/2024
|6/30/2024
| ||Pending
| ||Pending
Line 2,637: Line 2,658:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee);


Andrew Siref, MD
Andrew Siref, MD
Line 2,670: Line 2,691:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
Andrew Siref, MD
|3/20/2024
|3/20/2024
Line 2,680: Line 2,701:
|
|
|-
|-
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
Andrew Siref, MD
|3/20/2024
|3/20/2024
Line 2,726: Line 2,747:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);


Sumire Kitahara, MD
Sumire Kitahara, MD
Line 2,741: Line 2,762:
|
|
|-
|-
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||Pending
Line 2,793: Line 2,814:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|3/22/2024|| ||Pending|| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,800: Line 2,823:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc;
Teodora Popa (resident)
|3/19/2024
|3/19/2024
| ||Pending
| ||Pending
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"